In melanoma patients responding positively to treatment with nivolumab and pembrolizumab (combination of antibodies against programmed cell death protein 1/programmed cell death protein ligand 1 (PD1/PD-L1)), a significant decrease in exosomal PD-L1 expression was observed [62,63]. Here, PDCD1 is linked to melanoma.